Literature DB >> 1579757

A comparison of sample size methods for the logrank statistic.

E Lakatos1, K K Lan.   

Abstract

Several methods are available for sample size calculation for clinical trials when survival curves are to be compared using the logrank statistic. We discuss advantages and disadvantages of some of these methods, and present simulation results under exponential, proportional hazards and non-proportional hazard situations.

Mesh：

Year:  1992        PMID： 1579757     DOI： 10.1002/sim.4780110205

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  17 in total

1.  An asymptotic analysis of the logrank test.

Authors:  R L Strawderman
Journal:  Lifetime Data Anal       Date:  1997       Impact factor: 1.588

2.  Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.

Authors:  Ismail Jatoi; Hanna Bandos; Jong-Hyeon Jeong; William F Anderson; Edward H Romond; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2015-10-30       Impact factor: 13.506

3.  A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.

Authors:  Fang Xia; Stephen L George; Xiaofei Wang
Journal:  Stat Biopharm Res       Date:  2016-03-22       Impact factor: 1.452

4.  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Authors:  Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

5.  Power and sample size calculation for log-rank test with a time lag in treatment effect.

Authors:  Daowen Zhang; Hui Quan
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

6.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

7.  A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.

Authors:  L Shepstone; R Fordham; E Lenaghan; I Harvey; C Cooper; N Gittoes; A Heawood; T J Peters; T O'Neill; D Torgerson; R Holland; A Howe; T Marshall; J A Kanis; E McCloskey
Journal:  Osteoporos Int       Date:  2012-10       Impact factor: 4.507

8.  Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies.

Authors:  Tom Greene
Journal:  Methods Mol Biol       Date:  2021

9.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.

Authors:  Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens
Journal:  Lancet       Date:  2014-05-13       Impact factor: 79.321

10.  Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.

Authors:  Gérard Helft; Claude Le Feuvre; Jean Louis Georges; Didier Carrie; Florence Leclercq; Hélène Eltchaninoff; Alain Furber; Fabrice Prunier; Laurent Sebagh; Simon Cattan; Guillaume Cayla; Eric Vicaut; Jean-Philippe Metzger
Journal:  Trials       Date:  2013-02-21       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.